Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
To assess the relapse free-survival difference between patients with PIK3CA mutated and wild-type (WT) tumors and therefore validate PIK3CA mutation status as an important biomarker in women 70 years or older diagnosed with breast cancer.
OUTLINE:
Previously collected tissue samples are analyzed via mutation analysis of PIK3CA.
Age
70–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants with stage I breast cancer (T1N0M0) and estrogen-receptor status positive or unknown
Patients underwent lumpectomy with negative margins and were clinically node-negative
Clareo Health | Biomarkers in Tissue Samples From Older Women With Breast Cancer
